ClinicalTrials.gg
Not yet recruitingNCT07938112Updated Nov 16, 2026

Efficacy and Safety of Electroacupuncture in the Treatment of Esophageal Symptoms in Non-erosive Reflux Disease (NERD) Patients

An interventional study of Acupuncture needles in Non-erosive Reflux Disease (NERD), sponsored by Nanyang Technological University. Not yet recruiting at 1 site in Singapore. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Nanyang Technological University · Not applicable, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
21 Years to 75 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if acupuncture works to treat non-erosive reflux disease (NERD) patients. The main questions it aims to answer are:

  1. Electroacupuncture (EA) is superior to sham EA in terms of easing the symptom severity of NERD.
  2. Acupuncture is able to influence gastrointestinal function, autonomic regulation, and stress responses in NERD patients.

Participants will:

  1. Receive acupuncture treatment twice per week for 6 weeks.
  2. Leave plasma, serum, saliva, stool, and urine samples at baseline, mid-treatment, and end-of-treatment.
  3. Complete patient-reported-outcomes (PROs) at baseline, mid-treatment, and end-of-treatment
02

Conditions studied

  • Non-erosive Reflux Disease (NERD)
03

In context

Non-Erosive Reflux Disease

47 studies on the registry are indexed under Non-Erosive Reflux Disease; 8 are open to participants now.

This study's planned enrollment of 96 is below the median of 160 across 34 interventional studies indexed under Non-Erosive Reflux Disease.

Browse Non-Erosive Reflux Disease studies →

Lead sponsor

Nanyang Technological University is the lead sponsor of 53 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 21 to 75 years at the time of consent;
  • Presence of heartburn, regurgitation or chest pain before screening with a frequency of at least twice a week;
  • No evidence of esophageal mucosal injury on endoscopy within the past 5 years;
  • GERD-Q score ≥8 (indicating active GERD symptoms);
  • Ability and willingness to provide written to participate.

Exclusion criteria

Exclusion Criteria:

  • Structural or organic gastrointestinal disease, including but not limited to:

    1. gastrointestinal ,
    2. eosinophilic esophagitis,
    3. esophageal stricture, varices, or infections,
    4. active peptic ulcer disease,
    5. gastric or duodenal tumors;
  • Presence of alarming symptoms (e.g. severe dysphagia, hematemesis, unexplained weight loss, or hematochezia, etc.);
  • History of digestive tract surgery or esophageal interventions, including chemotherapy, radiotherapy, radiofrequency ablation, endoscopic mucosal resection, or cryotherapy;
  • Use of prohibited medical treatment:

    1. acupuncture treatment on the abdomen and chest within past 1 month,
    2. concomitant medication affecting gastrointestinal motility or visceral sensitivity (antidiarrheals, antidepressants, narcotic analgesics, anticholinergics, etc.),
    3. antibiotics, prebiotics, probiotics, or within 1 month prior to screening;
  • Presence of an implanted cardiac pacemaker;
  • History of to acupuncture, or needle phobia;
  • Severe psychiatric illness (e.g. schizophrenia, major depression, dementia), cognitive impairment, or other conditions likely to compromise adherence to study procedures;
  • Pregnant or breastfeeding;
  • Current participation in other clinical trials that could interfere with study outcomes.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Electroacupuncture (EA)

    The WHO Standardized Acupuncture Points Location will be used to identify the location of these acupoints: ST36 Zusanli, PC6 Neiguan, CV12 Zhongwan, LR3 Taichong, SP4 Gongsun; and auxiliary acupoints added according to symptom severity: PC7 Daling, ST44 Neiting, EX-HN3 Yintang, ST37 Shangjuxu, SP6 Sanyinjiao, LU7 Lieque. After sterilizing the skin, needles of 0.25 mm in diameter and 25-40 mm in length will be inserted into the acupoints to a depth of 10-30 mm outward and upward slightly. Needles will be lifted, thrust, and twirled evenly 3 times to achieve "de-qi". Paired electrodes of the EA apparatus will be attached transversely to the acupoint respectively with a continuous wave of 2/100 Hz and a current intensity of 1-5 mA (preferably with the skin around the acupoints shivering mildly without pain) for 30 min.

    Device: Acupuncture needles

  • Sham comparator
    Sham-electroacupuncture (SEA)

    The sham electroacupuncture group (SEA) penetrates acupuncture on non-acupuncture points (1 B-cun away from the acupuncture point and meridian). The same type of acupuncture needles will be used for SEA with the exact skin sterilization method. Insertion depth will be approximately less than 10 mm. The electrostimulator will not be switched on for these patients. All needles will be removed after 30 min of needle retention.

    Device: Acupuncture needles

Interventions

  • DeviceAcupuncture needles

    The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore.

06

What researchers measure

Primary outcomes

  1. Gastroesophageal Reflux Disease Questionnaire (GERDQ)

    ≥ 50% reduction in total GERD-Q score or normalization (\<8)

    Time frame: From enrollment to the end of follow-up at 16 weeks

  2. Gastrointestinal Symptom Rating scale (GSRS)

    ≥ 0.5 point decrease in mean GSRS Reflux domain value

    Time frame: From enrollment to the end of follow-up at 16 weeks

Secondary outcomes

  1. Quality of Life in Reflux and Dyspepsia questionnaire (QOLRAD)

    ≥ 0.5 point improvement on the mean QOLRAD score

    Time frame: From enrollment to the end of follow-up at 16 weeks

  2. Euro QoL (EQ-5D-5L)

    change in index utility

    Time frame: From enrollment to the end of follow-up at 16 weeks

  3. Hospital Anxiety and Depression Scale (HADS)

    categorical shift from ≥ 11 to \< 11 or ≥ 8 to \< 8, or ≥ 1.5 point reduction per HADS-A and HADS-D subscale

    Time frame: From enrollment to the end of follow-up at 16 weeks

  4. Visceral Sensitivity Index (VSI)

    ≥ 15% reduction from baseline

    Time frame: From enrollment to the end of follow-up at 16 weeks

  5. Esophageal Hypervigilance and Anxiety Scale (EHAS) Short Form

    ≥ 15% reduction from baseline

    Time frame: From enrollment to the end of follow-up at 16 weeks

  6. Simplified Constitution of Chinese Medicine Questionnaire (CCMQ)

    Time frame: At baseline

  7. Traditional Chinese medicine functional gastrointestinal disorders syndrome scale (TCM-FGID)

    (Total syndrome score before treatment - Total syndrome score after treatment) / Total syndrome score before treatment × 100%

    Time frame: From enrollment to the end of follow-up at 16 weeks

  8. Bang's blinding index (BBI)

    Time frame: End of first week and sixth week of intervention

  9. James' blinding index (JBI)

    Time frame: End of first week and sixth week of intervention

  10. Patient's global impression of change (PGIC)

    Time frame: From mid-treatment to the end of follow-up at 16 week

  11. Daily patient diary

    Time frame: From enrollment to the end of follow-up at 16 weeks

07

Study locations

1 site
  • Nanyang Technological University, School of Biological Sciences
    Singapore, S637551, Singapore
08

References and documents

Individual participant data

Plan to share: Yes — IPD sharing will be available upon request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Data will become available within 7 years after completion of the clinical trial.

Access criteria: Individual participant data (IPD) will be made available to qualified researchers upon request. To access the data, researchers must submit a formal request, which will be reviewed and approved by the data-sharing committee. Data access will be granted for research purposes only and will require adherence to data use agreements and ethics guidelines.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartEst.
Nov 2026
Primary completionEst.
Dec 2027
CompletionEst.
Mar 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938112
Lead sponsor
Nanyang Technological University
Responsible party
Linda Zhong (Associate Professor, Nanyang Technological University) — Principal investigator
First posted
Nov 16, 2026
Start date
Nov 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Linda LD Zhong, PhD
Contact
linda.zhong@ntu.edu.sg
+65 67911744
Huangyan Chen
Contact
huangyan001@e.ntu.edu.sg
+65 97663672
Linda LD Zhong, PhD
principal investigator · Nanyang Technological University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion